Mazdutide

Product Overview

Mazdutide (IBI362/LY3305677), developed by Eli Lilly and Innovent Biologics, is an analog of oxyntomodulin (OXM) that activates both GLP-1 and glucagon receptors. Approved in China as Xinermei in June 2025, it is the first marketed dual GCG/GLP-1 receptor agonist. Clinical data published in Nature, Lancet, and NEJM support its efficacy. Global Phase III trials are underway.

Mechanism of Action

Mazdutide mimics two natural gut hormones simultaneously: GLP-1 (reduces appetite, slows digestion, supports blood sugar control) and glucagon (increases energy expenditure, promotes fat burning, stimulates changes in liver, brain, and adipose tissue). The GLP-1 component counteracts glucagon's glucose-raising effect, creating a net benefit in both weight loss and glycemic control.

Key Benefits

Significant Weight Loss — Clinical trials demonstrate 11–14% body weight reduction over 48 weeks. Dual mechanism produces greater weight loss than GLP-1-only treatments through combined appetite suppression and increased energy expenditure.

Metabolic Health Improvement — Reduces waist circumference, blood sugar levels, cholesterol, and blood pressure beyond weight loss alone.

Liver Health — 10mg dose reduced liver fat by 68% after 32 weeks in MAFLD patients; 70% achieved normal liver fat levels after 48 weeks.

Convenient Once-Weekly Dosing — Single weekly injection provides sustained dual-receptor activation for consistent metabolic support.

References

1. Ji L, et al. Safety and efficacy of mazdutide (IBI362) in Chinese adults with overweight or obesity. *EClinicalMedicine.* 2022;54:101691.
2. Guideline for Chronic Weight Management and Clinical Practice of Anti-obesity Medications (2024). *Chin J Endocrinol Metab.* 2024;40(7):545–564.
3. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. *N Engl J Med.* 2023.